Adcetris
Active Ingredient(s): Brentuximab VedotinFDA Approved: * August 19, 2011
Pharm Company: * SEATTLE GENETICS
Category: Cancer
Brentuximab vedotin (INN; trade name Adcetris) is an antibody-drug conjugate medication used to treat relapsed or refractory Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL), a type of T cell non-Hodgkin lymphoma. It selectively targets tumor cells expressing the CD30 antigen, a defining marker of Hodgkin lymphoma and ALCL.[2] The drug is being jointly marketed by Millennium Pharmaceuticals outside the US and by Seattle Genetics in the US.[3&... [wikipedia]
* May have multiple approval dates, manufacturers, or labelers.Dosage List
Adcetris 50 mg/10.5ml Intravenous Injection, Powder, Lyophilized, for Solution
NDC: 51144-050
Labeler:
Seattle Genetics, Inc.